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Summary 
Title: Pharmacogenetics in the Treatment of Schizophrenia – Current Status 
Name: Joseph Wycoco 
Schizophrenia is a widespread mental disease that affects about 1% of the world 
population.  Because of the complex heritability of the disease as well as limited 
knowledge of the precise interconnected biochemical and genetic mechanisms 
underlying schizophrenia, there is wide variability in terms of antipsychotic drug 
efficacy, treatment effects, presence and severity of side-effects.   
With the completion of the mapping of the human genome, genome-wide association 
studies (GWAS) bring researchers one step closer to uncovering the molecular 
associations and pathways involving schizophrenia.    Three such current GWAS are 
examined, as the first GWAS determine genetic associations of 4 candidate genes, 
the second GWAS explores biological pathways involving histone methylation, 
immune-neuronal signaling, and the third GWAS attempts to discern the genotypic 
and phenotypic architecture of schizophrenia. 
Other current investigations involve the variability of the SV2C gene, and 
neurodevelopmental genes DISC1, NRG1, BDNF and NOTCH4. Variability of 
serotonin and dopamine pathways are also looked at as well as the variability of the 
CYP enzyme and association of voltage-gated calcium channels with schizophrenia. 
Finally current studies dealing with the pharmacogenetic association of genes and 
antipsychotic side-effects of hyperprolactinemia, extrapyramidal symptoms, QTc 
prolongation, extreme weight gain, and agranulocytosis are investigated. 
Key words: pharmacogenetics, schizophrenia, GWAS, genes, variability 
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Introduction 
Schizophrenia is a multi-factorial / polygenic complex mental disorder with a 
prevalence of approximately 1% of the world population and a heritability of up to 
80% [1] .   The clinical presentation of schizophrenia is usually described with 
positive symptoms (i.e. delusions, disordered thoughts and speech, tactile, audio or 
visual, olfactory or gustatory hallucinations) or negative symptoms (i.e. alogia, 
anhedonia, asociality or avolition). Onset of schizophrenia often occurs between late 
adolescence and young adulthood and its course is usually chronic, and eventually 
debilitating causing increased social and economic burden [1].   
Because the pathogenesis of schizophrenia is complex and influenced by both 
genetic and environmental factors, scientists have been challenged trying to uncover 
and identify the underlying mechanisms and pathways of this disease.  Traditionally, 
pharmacological therapy consisted of trial and error dosing of first and second 
generation antipsychotics as well as managing side-effects ranging from 
agranulocytosis, movement disorders, cardiac arrhythmias, to metabolic syndrome 
and hyperprolactinemia.  
Through continuing advances in molecular biology, genetics and 
biotechnologies, the whole human genome has finally been mapped.  Because of 
this accomplishment, new avenues of exploration into the human genetic code such 
as the genome-wide association studies are now possible.  Associations and 
pathways between genes and traits can now be further elucidated.  
Pharmacogenetic approaches allow researchers to study biological molecules 
such as CYP enzymes, cytokines, neurotransmitters and genes in order to 
6 
 
investigate and explore drug metabolism and transport.  As more knowledge is 
uncovered, the ultimate goal of personalized medicine comes closer. 
 This paper will explore three of the latest GWAS studies as well as the current 
status of investigations conducted in the post-GWAS era, where researchers uncover 
novel mechanisms of action, explore treatment effects, as well as study and attempt 
to manage the previously mentioned antipsychotic-induced side effects. 
Genome-Wide Association Studies (GWAS) 
Schizophrenia has a high heritability and there have been many studies 
attempting to discover the causative genetic factors [2].  Before the completion of the 
Human Genome Project and the International HapMap Project, cost and difficulties 
hampered investigators when trying to construct a comprehensive list of genetic 
variants in a genomic region. Investigators would select candidate genes based on 
either theories of schizophrenic etiology or through positional linkage and cytogenic 
studies [3].   
After genome mapping was completed, genome-wide association studies 
(GWAS) were conducted, whereby common genetic variants in different individuals 
(both cases and controls) were examined and compared to see if any variant could 
be associated with a particular trait.   The Schizophrenic Working Group of the 
Psychiatric Genomics Consortium (PCG) was founded in order to combine published 
and unpublished GWAS data into a single, systematic analysis in order to increase 
sample size and power of analytics when applied to schizophrenia.  These analyses 
focused on associations between single-nucleotide polymorphisms (SNPs) and the 
disease trait of schizophrenia.  In 2014, the PCG conducted a multi-stage GWAS of 
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schizophrenia, involving 36,989 cases and 113,075 controls and were able to identify 
128 independent associations spanning 108 conservatively defined loci.  This 
massive analysis suggested that schizophrenia has many common genetic variants 
of small effect sizes. 
A subsequent review published in 2015 [3] examined pre-GWAS era historical 
candidate gene association studies for common genetic variation. This particular 
review concluded that the historical candidate gene studies were significantly lacking 
in statistical power.  Through the confirmation of the PCG GWAS, 21 of the 25 
historical candidate genes  were excluded as  genetic risks for schizophrenia [2] .  
Only the four candidate genes DRD2, GRM3, TNF and NOTCH4 were considered to 
have genome-wide significant associations with schizophrenia [2].  These findings 
therefore illustrate the power of GWAS analysis and the potential to dramatically 
improve elucidation of schizophrenia etiologies, and to lead to improved treatments 
and outcomes. 
In order to better examine and identify the underlying biological mechanisms 
of genetic associations with psychiatric disorders, PCG conducted an analysis 
framework [4] to rank pathways across schizophrenia, major depression and bipolar 
disorder.  What they discovered was that pathways involving histone methylation, 
immune-neuronal signaling were significantly associated across all three psychiatric 
disorders. It was speculated that advances in pharmaceutical treatments could be 
possible as signaling pathways of these disorders are potentially better drug targets 
than individual genes [4].  
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A third GWAS [5] in 2015 took a different approach to investigating missing 
genomic heritability data.  Instead of just analyzing variance in large individual 
populations or combined data sets, these investigators attempted to measure and 
characterize the complex associations of both the genotypic and the phenotypic 
architecture of schizophrenia (Figure 1). Simply put, these investigators identified 
SNP sets without knowledge of the subjects’ status (case or control) and tested their 
associations with distinct phenotypical clinical feature-clusters of schizophrenia.  The 
researchers had found that 42 interactive SNP sets had greater than 70% risk of 
schizophrenia. They also determined that 98 SNP sets that had a 66% associated 
risk of schizophrenia accounted for 90% of the cases. These researchers concluded 
in their study that a limited number of genotypic networks were associated with 
several distinct clinical schizophrenic syndromes. 
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Figure 1. Panel A is a matrix corresponding to the GWAS data set.  Panel B is a matrix corresponding to the distinct phenotypic 
consequences using data at the symptom level from the Diagnostic Interview for Genetic Studies corresponding to the GWAS in 
Panel A.  Panel C cross-matched Panels A and B, revealing specific and distributed genotypic-phenotypic architectures 
“invisible” to traditional GWAS [Figure reproduced from Arnedo, J., et al., (2015) Uncovering the hidden risk architecture of the 
schizophrenias: confirmation in three independent genome-wide association studies. Am J Psychiatry, 172(2): p140] 
Current Investigations 
The results of the various GWAS has afforded investigators greater 
opportunity for more focused investigations into genetic variation that may complicate 
presentation signs of patients with schizophrenia, as well as into pharmacogenetic 
predictors of efficacy for the different types of antipsychotics. 
In one recent study, investigators looked at the genotypic variation of SNPs in 
the SV2C gene to see if it influenced atypical antipsychotics of the Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) study [6].  The synaptic 
vesicle protein 2C of the SV2C gene was previously identified as a potential 
modulator of nicotine’s protective effect on the incidence of Parkinson’s disease [7]. 
These investigators identified 18 SNPs in the promoter region of the genes that 
moderated smoking effects on Parkinson’s susceptibility.  It was found that instead of 
receiving a protective effect from nicotine, subjects homozygous for minor alleles of 
rs10214163 and rs30196 had increased incidence of Parkinson’s disease.  The 
SV2C protein is located on the surface of synaptic vesicles and is thought to have a 
role in synaptic function [8].  The protein also regulates tyrosine hydroxylase, which is 
a rate-limiting step for production of the neurotransmitters dopamine and 
norepinephrine [8].  Since SV2C is involved in both GABA and insulin transporter 
pathways, this protein was investigated for potential schizophrenia etiology and 
treatment effects [6]. Results of this study showed that one of the SNPs related to 
nicotine’s impact on Parkinson’s risk, rs10214163 [7], showed a correlative response 
with olanzapine and quetiapine, but not with risperidone or ziprasidone [6].  This 
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difference in preferential response may be due to the different binding affinities of 
these four various benzodiazepine derivatives [6].  Finally coding SNP rs227092 
showed a correlation with olanzapine response while coding SNP rs31244 showed a 
correlation with quetiapine response [6].  
It was shown that one third to one fifth of patients diagnosed with 
schizophrenia are resistant to drug treatment.  Several current studies explore the 
etiology of this treatment-resistant schizophrenia (TRS) [9]. 
One 2015 study [10] tested whether the genetic variability of 
neurodevelopmental genes DISC1, NRG1, BDNF and NOTCH4 had an impact on 
TRS patients.  DISC1 is involved in positioning of pyramidal neurons [11] in the 
cortex as well as neural progenitor proliferation regulation [12].  NRG1 is involved in 
neuronal migration, cell signaling and myelination [13]. BDNF is involved in neuronal 
differentiation [14], while NOTCH4 is responsible for signaling the maturation of 
neurons and glia from neural stem cells [15].  Results of the study showed that 
DISC1, NRG1, and BDNF did not show any significant correlation. However, 
NOTCH4 rs367398 did display a significant association with occurrence of treatment-
resistant schizophrenia and may play a role in the symptomatology of TRS [10].   
This same year, a study of the genetic variants of serotonin receptors 5-HT1A 
and 5-HTTLPR were examined to see if they had an influence on TRS [16].  When 
5HT1A receptors are activated by serotonin, dopamine is released into the prefrontal 
cortex, improving negative, cognitive and affective symptoms as well as modulating 
mood, cognition and motor behavior [17].  5-HTTLPR is an insertion/deletion 
polymorphism in the promoter region of the SLC6A4 gene which is a major regulator 
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of serotonin [18].  The study found that the 5-HT1A rs6295 variant and the 5-
HTTLPR polymorphisms had some influence on global patient functioning while 5-
HTTLPR specifically had an influence on negative symptoms of schizophrenia [16].  
However neither polymorphisms showed any influence on the development of TRS 
[16]. 
Another group of researchers [19] investigated DAT-VNTR, SERT-PR and 
SERT-in2 polymorphisms in regards to TRS.  The human dopamine transporter 
(DAT) has been shown to control dopamine neurotransmission and is a major site of 
action of psychostimulant drugs [20].   The SERT promoter region of the SLC6A4 
gene has an insertion/deletion polymorphism (SERT-PR) that can either present as a 
‘short’ or ‘long’ allele form.  SERT-in2 is a variable number tandem repeat (VNTR) 
within intron 2 [19].  Results of the study showed that TRS was associated with 
SERT-PR polymorphisms. ‘Short’ SERT-PR carriers were less likely to develop TRS 
compared to other variants of SERT-PR [19]. There was also a significant association 
between the interactions of DAT and SERT-in2 gene polymorphisms in regards to 
TRS [19].   
CYP enzymes metabolize almost all antipsychotics in the liver and are also 
found in the brain, impacting neurotransmitter and local breakdown of medication 
[21], and influencing personality features and psychiatric symptoms [22].  An 
investigation involved the CYP3A43 SNP rs472660 variant (which is involved in 
olanzapine response and clearance) and rs680055 (a putative functional marker on 
antipsychotic response) [23].  The results of this study showed a non-significant 
association for rs472660 SNP. However the rs680055 showed significant association 
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with lower treatment response across both genders [23] which was in line with a 
previous study on the influence of CYP3A43 on olanzapine [24] . 
Using the data of a GWAS, another 2015 study combined those results with 
gene pathway analysis using post-mortem brain tissue of schizophrenic patients and 
controls [25].  The post-mortem brain samples were analyzed to identify biological 
pathways and processes of GWAS-derived genes that associate with schizophrenia. 
Gene ontology (GO) enrichment analysis was performed on clusters of genes with 
high correlations of expression.  The investigators observed that significantly 
enriched cluster pathways belonged to calcium ion channel activity [25].  Supportive 
data from both the GWAS [2] and an analysis of rare disruptive mutations in 
schizophrenia [26] also pointed toward involvement of voltage-gated calcium 
channels. 
Side-Effects of Antipsychotics 
Hyperprolactinemia 
 Hyperprolactinemia (HPL) is a severe side effect that appears in up to 70% of 
patients receiving treatment with a number of FGA or SGA, particularly those patients 
using risperidone [27]. Side-effects of HPL include sexual dysfunction of both men 
and women, bone loss and is a risk factor for both breast and prostate cancer [28].  
Several mechanisms are hypothesized for antipsychotic-induced HPL [29].  One 
hypothesis is that the degree of HPL is related to the duration of dopamine receptor 
antagonism by antipsychotics.  Another hypothesis poses that the amount of 
circulating antipsychotic metabolites that cannot pass through the blood-brain barrier 
determines variability in stimulating prolactin release of the pituitary gland.  A third 
13 
 
hypothesis of variability concerns an antipsychotic’s simultaneous affinity towards 
both D2 receptors and 5-HT2 receptors. Aripiprazole has high affinity for D2 and 5-HT2 
receptors and does not cause HPL.  This property has led aripiprazole to be used as 
an adjunctive treatment for patients with risperidone-induced hyperprolactinemia [30].   
In determining a pharmacogenetic association with HPL, one study 
investigated DRD2 receptor gene SNPs of patients on olanzapine therapy and 
determined that rs2734842, rs6275 and rs6279 showed significant association with 
increased prolactin levels [31].  
Results for HPL association in other SNP targets have been mixed.  A 
previous study in 2009 showed a correlation between Taq1A A1 allele variants of 
DRD2 gene and higher prolactin levels of risperidone-treated boys [32]. However, a 
more recent study published in 2013 which examined the same Taq1A A1 allele 
variant found no such correlation with prolactin levels of patients receiving 
risperidone therapy [33].  
 Extrapyramidal Symptoms 
 With the introduction of first-generation antipsychotic (FGA) medications, 
movement disorders such as akathisia, tardive dyskinesia, and restless leg 
syndrome, were an unfortunate complication of treatment. Social stigma, non-
compliance of therapy and resulting risk of psychotic relapse compounded the 
problems [34].   Second-generation antipsychotics (SGAs) significantly reduced 
movement disorders side-effects, yet for some patients extrapyramidal symptoms 
persisted [34]. 
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While results were conflicting in hyperprolactinemia studies, the DRD2 / 
ANKK1 Taq1A genotypes were found to be significantly associated with SGA-
induced akathisia in one recent study [35].   Akathisia is a motor restlessness often 
accompanied by subjective distress. Selective blockade of DRD2 receptors induce 
movement disorders with the maximum blockade of these receptors in the basal 
ganglion resulting in the most severe symptoms [36].  In this study 47.6% of patients 
prescribed with FGAs developed akathisia compared to only 16.8% of patients 
prescribed with SGAs. However this advantage in patients prescribed with SGAs was 
reduced if they were Taq1A A1 variant positive. 
Another study investigated DRD2 polymorphism in relation tardive dyskinesia 
[37].  Tardive dyskinesia presents with involuntary, repetitive body movements that 
have a slow onset. While the study did not replicate previously reported 
polymorphisms, it did result in the discovery of two novel SNP associations in the 
DRD2 gene. The TaqI_D variant was associated with akathisia and the -141C variant 
was associated with tardive dyskinesia.   
Restless leg syndrome (RLS) is a disorder where the patient feels an 
irresistible urge to move the legs, accompanied or caused by uncomfortable, 
unpleasant sensations and occur in a circadian rhythm often starting in the evening, 
often disrupting sleep [38].  In 2015 investigators initiated a study, hypothesizing that 
there could be an association between RLS and circadian genes CLOCK and NPAS2 
[38].  They found a significant association of RLS with the CLOCK rs2412646 T allele 
polymorphism. The investigators postulated that antipsychotic-induced RLS in 
schizophrenia patients may be a mild form of akathisia occurring at night under 
circadian rhythm control.  
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QTc Prolongation 
Corrected QT interval (QTc) prolongation can be caused by antipsychotic 
medication, increasing the risk of cardiac arrhythmias such as torsades de pointes, 
which can result in sudden death [39].  Because of this risk, new antipsychotics being 
brought to market undergo a thorough TQc (TQT) study. This study was one such 
TQT investigation [40] of a relatively new antipsychotic called iloperidone.  
Iloperidone is a piperidinyl-benzisoxazole derivative with mixed D2/5-HT2a 
antagonism, meant to treat adult schizophrenia.  One of the requirements of the 
study was a pharmacogenomics sub analysis to identify potential risk factors.  
Determining these risk factors can be challenging because there is a higher 
prevalence of cardiovascular disease among people with schizophrenia compared to 
the general population [41]. Results of the TQT study revealed that 
CYP2D6*10(C100T) and KCNQ1 polymorphic alleles present significantly longer 
change in QTc interval in patients with iloperidone treatment compared to  patients 
on iloperidone treatment that do not have those specific polymorphisms.  
 
Weight Gain 
  Up to 30% of schizophrenic patients on acute or maintenance antipsychotic 
treatment experience weight gain as a side-effect [42]. Antipsychotic-induced weight 
gain (AIWG) can potentially lead to antipsychotic non-compliance, obesity, metabolic 
and vascular pathologies as well as premature mortality.   
 In one study, investigators looked at variants in the genes encoding IL-1β, IL-
2, IL-6 and BDNF in association with antipsychotic-induced weight gain [43].  
Inflammatory cytokines have been shown to mediate production of neurotransmitters 
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and neuropeptides related to the regulation of food intake [44].  Gene variants of IL-
1α, IL-1β, IL-RA, IL-6, and IL-6R have also been shown to have an association with 
obesity [45].  BDNF is a neurotrophin that can cause loss of appetite and is secreted 
by immune cells as a protective response during inflammation [46].  In this study, 19 
SNPs spanning IL-1β, IL-2, IL-6 and BDNF were investigated which covered over 
90% of the genetic variation [43].  The results of this study show that polymorphisms 
IL-1β rs4849127, rs16944, and rs1143634 increased the risk of AIWG.   Also 
BDFNVal66Met was shown to have mediating effects on AIWG where the Met allele 
(Met/Met + Met/Val) had a protective effect against excessive AIWG. Thus for chronic 
schizophrenia patients, these specific IL- β SNPs and BDNFVal66Met could 
potentially offer predictive outcomes for AIWG. 
 Another study in 2015 explored the possible association of the GABRA2 gene 
with AIGW [47]. GWAS revealed GABRA2 polymorphism as a potential candidate 
gene associated with AIGW. GABA has been investigated for its role in food intake 
as GABA agonists increased feeding behaviors in animal models [48]. The study 
revealed a significant association between GABRA2 and AIWG in schizophrenic 
patients of European descent.  GABRA2 could potentially become a pharmacological 
target to prevent AIWG.   
Agranulocytosis/Granulocytopenia 
Clozapine is a highly effective antipsychotic drug but also comes with a risk of 
the potentially lethal clozapine-induced agranulocytosis/granulocytopenia (CIAG) that 
occurs in 1% of treated individuals [49]. The major histocompatibility complex (MHC) 
plays a role in drug responses [50], and thus in 2014 the human leukocyte antigen 
(HLA) alleles were investigated in the largest genetic study of CIAG attempted so far 
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[51].   163 CIAG cases and 8,809,853 variants were compiled and genotyped along 
with 1,196 controls of European ancestry.  Results of the study determined two 
independent loci (HLA-DQB1 and HLA-B) in the MHC region that were identified to 
be associated with CIAG.  The study also isolated two amino acids (HLA-DQB1 126Q 
and HLA-B 158T) but could not determine whether they caused or were only risk 
factors for CIAG.  Testing for these two risk factors would not be helpful as such a 
test would only have a sensitivity of 0.36 and a specificity of 0.89.  A predictive test 
determining a “safe” group using these two risk factors would be inaccurate because 
of the low prevalence of CIAG, where less than half of the cases in this study carried 
either of these uncommon risk factors [51].  
Another experiment in 2015 investigated the genetic susceptibility of CIAG 
using in vitro lymphoblastic cell lines exposed to various concentrations of clozapine 
and measured cell viability after 48 hours [52].  The hypothesis was that clozapine 
toxicity in lymphoblasts could share molecular mechanisms with the agranulocytosis 
etiology.  A GWAS was performed for this in vitro model as well as an investigation of 
the MHC region [52] as was done in the previous GWAS [51].   
Interestingly, the investigators did not find involvement of the MHC region in 
lymphoblast cell vitality after clozapine exposure [52].  They believed that the 
unicellular model may not have been able to replicate the model of a complete multi-
cellular immunological system.  However their study was able to show a clozapine-
induced viability reduction in lymphoblasts that was a highly heritable (h2 = 0.76), 
complex polygenic trait that involved a modest number of loci with small effect as 
opposed to a small number of loci with large effect.  The investigators also identified 
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PRG4 and MDFIC as possible candidate genes associated with clozapine-induced 
reduced cell viability.   
 
 
Conclusion 
Pharmacogenetic and pharmacogenomic studies of schizophrenia and its 
therapeutic treatments have started to uncover various genetic and environmental 
factors that contribute to the variability of treatment efficacy or failure.  Genetic 
variances of CYP liver enzymes influence treatment success or failure as well as 
potential side effects.   
 Polymorphisms of dopamine, serotonin and immune-response pathways can 
influence pharmacological treatment efficacy or presence and severity of side-effects 
such as agranulocytosis, movement disorders, arrhythmias, weight gain, and 
hyperprolactinemia.   
 Unfortunately precise mechanisms of action of antipsychotic medication is still 
unclear. Many underlying molecular pathways of both disease and treatment remain 
unclear as researchers struggle with the reliability of experimental data born from 
low-power and limited sample size studies. 
 The goal of pharmacogenetics is to determine individually-tailored 
antipsychotic treatment based on genetic, environmental and clinical data. As 
knowledge and technology improves, this goal comes closer and closer to fruition 
through the continued experimentation and persistence of researchers. 
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